Language

I’m a radiation oncologist and researcher focused on clinical radiotherapy, oncology data science, molecular biomarkers, radiomics, and practical medical AI. My clinical work covers radiotherapy broadly, with a special focus on genitourinary and gastrointestinal cancers.

Full name: Konrad Grzegorz Stawiski
Nationality: Polish
E-mails: konrad@konsta.com.pl, konrad.stawiski@umed.lodz.pl, konradg_stawiski@dfci.harvard.edu, kstawisk@broadinstitute.org
Selected links: Harvard Catalyst, Radioonkolog.pl, ORCID, PubMed, OpenAlex, Google Scholar, GitHub

Summary

Konrad G. Stawiski is a board-certified radiation oncologist and clinical-translational researcher focused on GU/GI radiotherapy, bladder, prostate and rectal cancer care, radiomics, omics biomarkers, radiation-toxicity modeling, and practical medical AI.

He is a Visiting Assistant Professor of Radiation Oncology at Dana-Farber Cancer Institute, an Assistant Professor at the Medical University of Lodz, and Deputy Head of a 34-bed Brachytherapy and General Oncology Department at Copernicus Memorial Hospital in Lodz.

The current Google Scholar profile lists 97 records, an h-index of 19, and 1,095 citations. He is Partner PI and Polish group lead in the ERA PerMed miRPOC consortium, PI of the NCN PRELUDIUM and Radonek-AI projects, co-inventor on circulating microRNA patent families, and a clinical-trial subinvestigator in phase I/II-III oncology studies.

His research outputs include selected open research software and digital-health tools, translational biomarker studies, radiotherapy-data pipelines, clinical AI work, and editorial service as an Editorial Board Member of BMC Cancer.

Employment history

2026 - present: Visiting Assistant Professor of Radiation Oncology, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
2024 - present: Assistant Professor, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland
- Supervisor of the “Artificial Intelligence in Oncology” Students’ Scientific Group.
- Lecturer in Biostatistics, Translational Medicine, Research Methodology, and AI, including data mining and deep learning.
- Engaged in cancer research, focusing on bioinformatics and omic data analysis (radiomics, NGS sequencing - miRNA-seq, bulk/sc RNA-seq, WXS).
- Polish group lead in the ERA PerMed miRPOC international consortium.
2023 - present: Radiation Oncologist, Deputy Head of Department of Brachytherapy and General Oncology, Regional Oncology Centre, Copernicus Memorial Hospital, Lodz, Poland
- Deputy clinical lead for a 34-bed ward, coordinating external-beam radiotherapy, brachytherapy, concurrent chemoradiotherapy, and general oncology inpatient care.
- Radiation oncologist with a broad radiotherapy practice and special focus on genitourinary and gastrointestinal cancers, especially prostate, bladder, and rectal cancer, including prostate radiotherapy, bladder-preserving trimodality treatment/radio-chemotherapy, rectal cancer chemoradiotherapy, and multidisciplinary uro-oncology (see https://radioonkolog.pl for clinical activities). Serving as subinvestigator in commercial and non-commercial clinical trials.
- Performing stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), radiochemotherapy, and radioimmunotherapy.
2022 - 2023: Research Fellow in Radiation Oncology (Mouw Lab and Carvalho Lab), Dana-Farber Cancer Institute/Harvard Medical School/Broad Institute of MIT and Harvard, Boston, MA, USA
2021 - 2023: Research and Teaching Assistant, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland
2018 - 2023: Radiation Oncology Resident Physician, Regional Oncology Centre, Copernicus Memorial Hospital, Lodz, Poland
- Physician in Department of Radiotherapy and on-call physician in Radiotherapy and Oncology Ward (reference: Prof. Jacek Fijuth, M.D., Ph.D.),
- Additional experience as on-call physician in Hematooncology Ward (reference: Prof. Piotr Smolewski, M.D., Ph.D.).
2017 - 2018: Bioinformatics and Medical Informatics Specialist, Department of Biostatistics and Translational Medicine, Medical University of Lodz, Poland
2016 - 2017: Medical Post-graduate Internship, Clinical Hospital of the Ministry of the Interior and Administration in Lodz, Lodz, Poland

Clinical, research and software profile

Broad radiotherapy practice with a genitourinary and gastrointestinal focus; radiomics and radiotherapy-data pipelines; translational biomarkers; reproducible oncology analyses; and selected research-software and digital-health projects.

Academic profileConcise scientific CV for review and collaboration.

English PDF English DOCX Polish PDF Polish DOCX

Full academic CVComprehensive archive with the complete publication record and detailed service history.

English full PDF English full DOCX Polish full PDF Polish full DOCX

Contact

Clinical and translational work

From clinical practice to tools and publications

Clinical radiotherapyGU and GI focus, SBRT/SRS, brachytherapy, radiochemotherapy

Data and evidenceDICOM RT, radiomics, miRNA, RNA-seq, WXS, clinical datasets

Analysis and validationBiostatistics, machine learning, interpretable prediction models

OutputsClinical trials, publications, open software, digital-health projects, patient resources

Focus areas

Radiation oncology Biomarkers and imaging Medical AI Open tools

Education

2023: Board Certification in Radiation Oncology, Medical Examinations Center (CEM) in Poland.
2016 - 2021: Doctor of Philosophy (PhD) (doctorate), Department of Biostatistics and Translational Medicine (reference: Wojciech Fendler, M.D., Ph.D.; https://biostat.umed.pl):
- Dissertation: Głębokie sztuczne sieci neuronowe w integracji profilu ekspresji krążących i wewnątrzkomórkowych cząsteczek miRNA pacjentów z rakiem trzustki. (Deep learning-based integration of circulating and cellular miRNA expression of pancreatic cancer.)
2017: Full medical license in Poland (PWZ: 3347648)
2010 - 2016: Doctor of Medicine (MD) (6-year M.D. Program; grade: very good), Faculty of Medicine, Medical University of Lodz (Poland)

Internships

2026: Prof. Franciszek Walczak NAWA scholarship for a 6-month research stay at Dana-Farber Cancer Institute/Harvard Medical School focused on radiotherapy research in bladder cancer, including bladder-sparing strategies.
2022-2023: Bekker NAWA (6 months) research fellowship in Dana-Farber Cancer Institute/Harvard Medical School/Broad Institute of MIT and Harvard, Boston, MA, USA (reference: Kent Mouw, M.D., Ph.D.)
2016: ERASMUS+ research internship at the EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging, University of Cambridge, Cambridge, UK, focused on real-time TRUS-MRI fusion software for prostate cancer biopsy (reference: Prof. John Aston, Ph.D.)
2015: IFMSA research exchange (6 weeks), Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Upstate Medical University, Syracuse, NY, USA (reference: Stephen J. Glatt, Ph.D.)
2014: neurosurgical clinical clerkship (3 weeks), University Hospital Southampton NHS Trust, Southampton, UK (reference: Paul Grundy, M.D.)
2013: medical clinical clerkship (4 weeks), Mubarak Al Kabeer Hospital, Kuwait City, Kuwait (reference: Ibrahim T. Lasheen, M.D.)

Research grants, funded projects and innovation work

2023 - present: ERA PerMed Consortium (Joint Transnational Call 2022), miRPOC - miRNA as biomarkers in early detection and personalised treatment in ovarian cancer; total consortium budget approximately EUR 1,000,000; Partner PI / Polish group lead at Medical University of Lodz; consortium with Cancer Registry of Norway/Oslo University Hospital, German Cancer Research Center and Brigham and Women’s Hospital/Harvard Medical School.
2023 - 2024: Radonek-AI - virtual oncology patient assistant, PLN 70,000, Student Scientific Circles Create Innovations programme, Polish Ministry of Education [PI]
2019 - 2022: NCN PRELUDIUM [ID: UMO-2018/29/N/NZ5/02422], Deep artificial neural networks in the integration of the expression profile of circulating and intracellular miRNA molecules in pancreatic cancer patients. 209 860 PLN [PI]
2014 - 2015: Ministry of Science and Higher Education Generation of the Future [ID: MNiSw/2014/DIR/379/GPII], PancreApp: application of the eight-dimensional Shepard approximation in the individualization of nutritional recommendations, with particular emphasis on chronic pancreatitis, PLN 37,800 [PI]
2017 - 2018: Specialist in bioinformatics and medical informatics (building an internet platform to collect data for the research purposes of the project) in the project “Lodz Program for HNSCC Prevention” [ID: POWR.05.01.00-00-0011/16] co-financed by the European Union as part of the European Social Fund (European Social Fund, 1 792 260 PLN)
2019-2021: Researcher in the study “Predictive Biomarkers of Radiation Toxicity (PBRTox)” [ID: POIR.04.04.00-00-2280/16] under the supervision of prof. Wojciech Fendler (Foundation for Polish Science; 1 999 651 PLN)
2014-2016: Researcher in the study “Profile of circulating microRNAs in the diagnosis of rare forms of diabetes” [ID: 2012/05/E/NZ5/02130] under the supervision of prof. Wojciech Fendler (NCN SONATA BIS; 1 489 800 PLN)

Awards, honours and scholarships

2025: Prof. Franciszek Walczak NAWA Programme Scholarship, Polish National Agency for Academic Exchange; one of 31 awardees selected from 125 applications in the 2025 call (25% success rate; funding up to PLN 29,500/month), for a 6-month Dana-Farber / Harvard Medical School fellowship on bladder-preserving treatment strategies in muscle-invasive bladder cancer; institutional report: application score 94/100.
2025: First place for final research project in the Harvard Medical School / Polish Medical Research Agency Clinical Scholars Research Training programme, for a project on rectal cancer radiochemotherapy.
2022: Rector’s Award for Research Achievements in 2021, Medical University of Lodz, team award for publication series on urologic cancer (12.919 IF).
2022: Best biostatistics Ph.D. thesis in 2021 (Awarded by StatSoft Polska).
2022: Implementation Activity Award of Polish Ministry of Science, for work involving the implementation of diagnostic tests based on free-circulating microRNAs into clinical practice.
2021: Scholarship of Polpharma Scientific Foundation for best Ph.D. students, awarded for the dissertation on deep artificial neural networks integrating circulating and intracellular miRNA profiles in pancreatic cancer.
2020: Scholarship for the best Ph.D. students at the Medical University of Lodz.
2019: Scholarship for the best Ph.D. students at the Medical University of Lodz.
2018: Scholarship for the best Ph.D. students at the Medical University of Lodz.
2017: Scholarship for the best Ph.D. students at the Medical University of Lodz.
2016: Scholarship for the best Ph.D. students at the Medical University of Lodz.
2016: Scholarship of the City of Lodz for the best Ph.D. students.
2016: Winner of Adzuna’s Polish “Graduate of the Year” contest.
2015: Scholarship of Minister of Science and Higher Education & Minister of Health of Republic of Poland for outstanding achievements for students in the academic year 2015/2016.
2015: Scholarship of Marshal of the Lodzkie Region (highest degree)
2014: Distinction in a nationwide competition “Studencki Nobel” (Eng. “Student’s Nobel Prize”).
2014: Special Award for the Youngest Winner of the Session at the conference 10. International & 52. Polish Training & Scientific Medical Congress of Students’ Scientific Societies and Junior Doctors “Juvenes Pro Medicina” 2014 in Łódź (founder: Aldona Ochęcka-Szymańska M.D., Ph.D.)
2013: Scholarship of Minister of Science and Higher Education of Republic of Poland for outstanding achievements for students in the academic year 2013/2014;

Patents and commercializations

WO2023283476A2, CA3223723A1, and AU2022306397A1, entitled “Circulating microRNA signatures for pancreatic cancer”; assignees include Medical University of Lodz and Dana-Farber Cancer Institute Inc.
EP3565903, US20200123614A1, US11214839B2, and US12385099, entitled “Circulating microRNA signatures for ovarian cancer”; assignees include Medical University of Lodz, Brigham and Women’s Hospital Inc., and Dana-Farber Cancer Institute Inc.; patent record indexed by PublicUM; publicly described as under commercialization/licensing efforts with Aspira Women’s Health (A15876-ELA-ASPIRA).

Research

Bibliometrics

H-index according to Google Scholar: 19
(citations = 1095; papers/abstracts = 97)

Citation and publication trends from Google Scholar. For formal publication review, use PubMed, ORCID, and OpenAlex as authoritative records.

97Google Scholar records

1,095Google Scholar citations

19H-index

2013-2026Publication years

Citations by year

02013

02015

32017

342018

432019

692020

1502021

1252022

1512023

1932024

2002025

1122026

Publication records by year

12013

22015

92017

42018

72019

62020

92021

192022

72023

172024

92025

42026

Selected publications and contributions

First author / GU translational oncology: Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma. Molecular Oncology. 2026 Jun 1. doi: 10.1002/1878-0261.70276. Role: first author; tumor immune microenvironment and platinum-treated urothelial carcinoma.
Bladder cancer / DFCI-Broad collaboration: Zhou Y, Borcsok J, Adib E, Kamran SC, Neil AJ, Stawiski K, et al. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 2023;9:eadg2263. doi: 10.1126/sciadv.adg2263. Role: co-author in translational bladder cancer work aligned with bladder-preserving research.
Clinical AI / urologic oncology: Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Rozanski W, Soria F, et al. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology. 2022;5:109-112. Role: clinical-AI and prediction-modeling collaborator.
Research software / omics modeling: Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczynski A, et al. OmicSelector: automatic feature selection and deep learning modeling for omic experiments. bioRxiv. 2022. doi: 10.1101/2022.06.01.494299. Role: first author and software lead.
miRNA biomarker validation: Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, et al. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches. Frontiers in Oncology. 2024;14:1389066. Role: first author; machine-learning validation of circulating miRNA biomarkers.
Patent-linked translational diagnostics: Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, et al. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6:e28932. Role: computational biomarker collaborator in patent-linked translational work.
Radiation biomarker work: Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, et al. Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study. Radiotherapy and Oncology. 2023;185:109731. Role: biomarker and radiation-response collaborator.
Radiation toxicity / dose-volume analytics: Nowicka Z, Kuna K, Laszczych M, Lazar-Poniatowska M, Sobocki BK, Stawiski K, et al. Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques. Physics and Imaging in Radiation Oncology. 2024;30:100593. Role: radiotherapy data and prediction-modeling collaborator.

Authoritative full records: PubMed, ORCID, OpenAlex, and Google Scholar.

Google Scholar publication records

B Tomasik, M Jąkalski, M Bieńkowski, J Teodorczyk, BK Sobocki, … Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics Journal of Translational Medicine 2026: 24 (1), 587 [citations: 1]
JW Webber, L Wollborn, S Mishra, S Alimena, B Testino, K Stawiski, … A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer Scientific Reports 2026 [citations: 0]
K Kuna, J Burzyński, D Mikulski, B Sobocki, A Papis-Ubych, K Stawiski, … Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy Contemporary Oncology/Współczesna Onkologia 2026: 29 (1) [citations: 0]
K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere, J Lee, … Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma Molecular Oncology 2026: doi: 10.1002/1878-0261.70276 [citations: 0]
M Golinska, A Rycerz, M Sobczak, J Chrzanowski, K Stawiski, W Fendler Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis Frontiers in Immunology 2025: 16, 1619434 [citations: 12]
M Pajdziński, J Burzyński, A Zięba, N Jędrzejczak, J Fijuth, K Stawiski 4474 Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study Radiotherapy and Oncology 2025: 206, S919-S920 [citations: 0]
K Stawiski, A der Rycerz, J Burzyński, K Kasper, W Fendler 4567 Radonek-Fine-Tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation Radiotherapy and Oncology 2025: 206, S2417-S2418 [citations: 0]
MM Pietrzak, W Pietruszewska, M Barańska, A Rycerz, K Stawiski, … Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies Biomedicines 2025: 13 (2), 511 [citations: 0]
D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microrna signatures for ovarian cancer US Patent 2025: 12,385,099 [citations: 0]
D Chowdhury, W Fendler, K Stawiski Circulating microrna signatures for pancreatic cancer US Patent App. 2025: 18/577,387 [citations: 0]
S Kołowacik, BJ Bińkowski, K Stawiski, J Drożdż Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation Polish Heart Journal (Kardiologia Polska) 2025: 83 (2), 203-206 [citations: 0]
K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere Rodero, J Lee, … Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma bioRxiv 2025: 2025.02. 27.640395 [citations: 0]
FLF Carvalho, J Lee, N Kalavros, Y Zhou, D Michaud, I Stelter, H Siddiqui, … Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer bioRxiv 2025: 2025.09. 08.674862 [citations: 0]
Z Nowicka, K Kuna, M Łaszczych, M Łazar-Poniatowska, BK Sobocki, … Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques Physics and Imaging in Radiation Oncology 2024: 30, 100593 [citations: 12]
P Brady, A Yousif, N Sasamoto, AF Vitonis, W Fendler, K Stawiski, … Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use Frontiers in Reproductive Health 2024: 6, 1360417 [citations: 8]
A Puła, T Robak, I Dróżdż, K Stawiski, A Rycerz, M Misiewicz, P Robak Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens-pilot study Leukemia & Lymphoma 2024: 65 (2), 257-264 [citations: 4]
Z Nowicka, K Kuna, M Łaszczych, K Stawiski, B Tomasik, W Fendler Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e52 [citations: 3]
K Stawiski, RT Fortner, L Pestarino, SU Umu, R Kaaks, TB Rounge, … Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches Frontiers in oncology 2024: 14, 1389066 [citations: 3]
Z Nowicka, K Kuna, K Stawiski, J Sołek, M Świderek, A Papis-Ubych, … Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes Head & Neck 2024: 46 (2), E10-E17 [citations: 1]
D Mikulski, M Nowicki, I Dróżdż, E Perdas, P Strzałka, K Kościelny, … MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation Biomarker Research 2024: 12 (1), 42 [citations: 1]
K Stawiski, M Bilski, J Nowak-Potemska, M Bilewicz, J Fijuth Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy International Journal of Radiation Oncology, Biology, Physics 2024: 120 (2), e549-e550 [citations: 1]
JW Webber, L Wollborn, S Mishra, AF Vitonis, DW Cramer, RT Phan, … Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass Gynecologic Oncology 2024: 190, 124-130 [citations: 1]
M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth 1994: Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM-a pilot study Radiotherapy and Oncology 2024: 194, S1165-S1168 [citations: 0]
K Stawiski, M Pajdziński, A Zięba, M Masłowski, J Fijuth 3178: Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy. Radiotherapy and Oncology 2024: 194, S3165-S3166 [citations: 0]
CJ Magnani, VD DAndrea, K Stawiski, I Stelter, T Hanlon, L Jia, AS Kibel, … AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior European Urology 2024: 85, S219-S220 [citations: 0]
F Mohammed, K Stawiski, HS Musa, SK Owolabi, S Abubakar, SO Rotimi, … Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in … Cancer Research 2024: 84 (6_Supplement), 6432-6432 [citations: 0]
Z Nowicka, K Kuna, M Łaszczych, M Łazar-Poniatowska, BK Sobocki, … Physics and Imaging in Radiation Oncology Oncology 2024: 30 [citations: 0]
BA Łochowska, K Stawiski, K Kuna, Z Nowicka, M Łochowski, J Fijuth Predicting overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab-a Polish real-world single-center experience Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2024: 9 (3), 190-196 [citations: 0]
A Suleja, M Bliski, E Laukhtina, P Rajwa, K Stawiski, M Miszczyk Radioterapia stereotaktyczna (SBRT) w leczeniu pierwotnie zlokalizowanego raka nerkowokomórkowego (RCC)-przegląd systematyczny i metaanaliza Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY 2024: 9 (Suppl. 1) [citations: 0]
FLF De Carvalho, J Lee, K Bi, B Titchen, K Stawiski, J Park, A Garza, … Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer Cancer Research 2024: 84 (6_Supplement), 7041-7041 [citations: 0]
M Miszczyk, Ł Magrowski, T Krzysztofiak, R Stando, W Majewski, … Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group … Radiotherapy and Oncology 2023: 183, 109632 [citations: 29]
Y Zhou, J Börcsök, E Adib, SC Kamran, AJ Neil, K Stawiski, D Freeman, … ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer Science advances 2023: 9 (47), eadg2263 [citations: 25]
K Elias, U Smyczynska, K Stawiski, Z Nowicka, J Webber, J Kaplan, … Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles Nature communications 2023: 14 (1), 3350 [citations: 20]
Z Nowicka, B Tomasik, D Kozono, K Stawiski, T Johnson, D Haas-Kogan, … Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study Radiotherapy and Oncology 2023: 185, 109731 [citations: 12]
J Malinowski, W Pietruszewska, K Stawiski, MM Pietrzak, M Barańska, … High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development Cancers 2023: 15 (14), 3716 [citations: 5]
M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy-a pilot study Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory 2023: 8 (4), 274-283 [citations: 1]
K Stawiski, J Perera-Bel, A Rodriguez-Vida, NJ Rodero, KW Mouw, … Assessing tumor-infiltrating immune cells and outcomes with cisplatin-versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum … Journal of Clinical Oncology 2023: 41 (16_suppl), 4583-4583 [citations: 0]
M Jobczyk, K Stawiski, M Kaszkowiak, P Rajwa, W Różański, F Soria, … Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer European urology oncology 2022: 5 (1), 109-112 [citations: 37]
K Mieczkowski, K Kitowska, M Braun, B Galikowska-Bogut, … FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer Molecular Oncology 2022: 16 (15), 2823-2842 [citations: 22]
Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski, M Ciążyńska, … The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy Cancers 2022: 14 (16), 3844 [citations: 17]
M Panek, K Stawiski, M Kaszkowiak, P Kuna Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model … Frontiers in immunology 2022: 13, 746360 [citations: 14]
K Stawiski, M Kaszkowiak, D Mikulski, P Hogendorf, A Durczyński, … OmicSelector: automatic feature selection and deep learning modeling for omic experiments BioRxiv 2022: 2022.06. 01.494299 [citations: 12]
W Fendler, B Tomasik, K Atkins, K Stawiski, J Chałubińska-Fendler, … The clinician’s guide to radiotherapy complications Polskie Archiwum Medycyny Wewnętrznej 2022: 132 (1) [citations: 10]
A Gockley, K Pagacz, S Fiascone, K Stawiski, N Holub, K Hasselblatt, … A translational model to improve early detection of epithelial ovarian cancers Frontiers in Oncology 2022: 12, 786154 [citations: 8]
M Miszczyk, J Rembak-Szynkiewicz, Ł Magrowski, K Stawiski, … The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated radiotherapy for localized prostate cancer Cancers 2022: 14 (7), 1613 [citations: 8]
EJ Bobeff, M Bukowiecka-Matusiak, K Stawiski, K Wiśniewski, … Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage Journal of Clinical Medicine 2022: 11 (2), 380 [citations: 6]
S Kubik, D Jesionek-Kupnicka, K Stawiski, J Fijuth, … Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma Journal of Obstetrics and Gynaecology 2022: 42 (6), 2248-2254 [citations: 5]
EJ Bobeff, K Stawiski, PA Stanisławska, BJ Posmyk, K Wiśniewski, M Bryl, … Validation of the elderly traumatic brain injury score: observational case control study World neurosurgery 2022: 161, e464-e472 [citations: 5]
D Chowdhury, KM Elias, W Fendler, K Stawiski Circulating microRNA signatures for ovarian cancer US Patent 2022: 11,214,839 [citations: 3]
K Stawiski, M Maslowski, W Maslowska, M Kordzinska, B Lochowska, … Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e150 [citations: 0]
M Panek, K Stawiski, M Kaszkowiak, P Kuna Cytokine TGFbeta gene polymorphisms in asthma Frontiers in Immunology 2022: 13 [citations: 0]
A Napieralska, J Bochenek-Cibor, A Chyrek, M Konkol, E Pawłowska, … Improving Education in Radiation Oncology in Poland International Journal of Radiation Oncology, Biology, Physics 2022: 114 (1), e4-e5 [citations: 0]
EJ Bobeff, M Bukowiecka-Matusiak, K Stawiski, K Wisniewski, … Kordzi nska J. Clin. Med 2022: 11, 380 [citations: 0]
D Mikulski, M Nowicki, I Dróźdż, E Perdas, P Strzałka, K Kościelny, … Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy. Acta Haematologica Polonica 2022: 53 [citations: 0]
M Miszczyk, J Ciepał, R Stando, O Masri, I Jabłońska, K Stawiski, … The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy International Journal of Radiation Oncology, Biology, Physics 2022: 114 (3), e231 [citations: 0]
M Miszczyk, E Staniewska, I Jabłońska, A Lipka-Rajwa, K Stawiski, … Volumetric staging in radiotherapy for oropharyngeal cancers Tumori Journal 2022: 108 (6), 586-591 [citations: 0]
P Robak, D Jarych, D Mikulski, I Dróżdż, E Węgłowska, A Kotkowska, … The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib Cancers 2021: 13 (5), 951 [citations: 23]
B Tomasik, A Papis-Ubych, K Stawiski, J Fijuth, P Kędzierawski, … Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy International Journal of Radiation Oncology Biology* Physics 2021: 111 (5), 1237-1249* [citations: 18]
P Michał, S Konrad, K Piotr TGF-beta gene polimorphisms as risk factors for asthma control among clinic patients Journal of Inflammation 2021: 18 (1), 28 [citations: 13]
L Lee, B Howitt, T Cheng, M King, K Stawiski, W Fendler, D Chowdhury, … MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma Gynecologic oncology 2021: 163 (3), 453-458 [citations: 9]
D Mikulski, I Dróżdż, E Perdas, K Stawiski, M Nowicki, M Misiewicz, … Changes in the microrna expression profile in patients undergoing autologous steam cell transplantation Blood 2021: 138, 4789 [citations: 5]
M Miszczyk, W Majewski, K Stawiski, K Rasławski, P Rajwa, I Jabłońska, … Prognostic factors in postoperative radiotherapy for prostate cancer-tertiary center experience Radiology and Oncology 2021: 55 (2), 203 [citations: 4]
Z Nowicka, R Bibik, R Stando, W Fendler, K Stawiski, B Tomasik A link between seasonality and radiation-related toxicity: The big time or time will tell? Radiotherapy and Oncology 2021: 161, 257-258 [citations: 2]
ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence BMC genomics 2021: 22 (1), 327-327 [citations: 1]
ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence (vol 19, 37 … BMC GENOMICS 2021: 22 (1) [citations: 0]
B Małachowska, B Tomasik, K Stawiski, S Kulkarni, C Guha, … Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis International Journal of Radiation Oncology Biology* Physics 2020: 106 (2), 390-402* [citations: 64]
M Jobczyk, K Stawiski, W Fendler, W Różański Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC … Cancer Medicine 2020: 9 (11), 4014-4025 [citations: 59]
P Robak, I Dróżdż, D Jarych, D Mikulski, E Węgłowska, M Siemieniuk-Ryś, … The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients Cancers 2020: 12 (9), 2569 [citations: 28]
Ł Kuncman, K Stawiski, M Masłowski, J Kucharz, J Fijuth Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer Strahlentherapie und Onkologie 2020: 196 (11), 998-1005 [citations: 27]
M Braun, D Piasecka, B Tomasik, K Mieczkowski, K Stawiski, A Zielinska, … Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma Cancers 2020: 12 (9), 2713 [citations: 17]
Z Nowicka, B Tomasik, DE Kozono, K Stawiski, TJ Johnson, … Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation International Journal of Radiation Oncology, Biology, Physics 2020: 108 (3), e536 [citations: 0]
Z Nowicka, K Stawiski, B Tomasik, W Fendler Extracellular miRNAs as biomarkers of head and neck cancer progression and metastasis International journal of molecular sciences 2019: 20 (19), 4799 [citations: 45]
A Zmyslowska, A Waszczykowska, D Baranska, K Stawiski, M Borowiec, … Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome Developmental Medicine & Child Neurology 2019: 61 (3), 359-365 [citations: 27]
EJ Bobeff, J Fortuniak, B Bryszewski, K Wiśniewski, M Bryl, K Kwiecień, … Mortality after traumatic brain injury in elderly patients: a new scoring system World neurosurgery 2019: 128, e129-e147 [citations: 26]
M Kotlicka-Antczak, MS Karbownik, K Stawiski, A Pawełczyk, N Żurner, … Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state European Psychiatry 2019: 58, 72-79 [citations: 26]
M Zakrzewska, R Gruszka, K Stawiski, W Fendler, J Kordacka, … Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors BMC cancer 2019: 19 (1), 544 [citations: 17]
EJ Bobeff, BJ Posmyk, K Bobeff, J Fortuniak, K Wiśniewski, K Stawiski, … Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study Journal of Neurological Surgery Part A: Central European Neurosurgery 2019: 80 (06 … [citations: 5]
L Kuncman, K Stawiski, M Maslowski, J Wilczynska, J Bury, J Fijuth FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer. International Journal of Radiation Oncology, Biology, Physics 2019: 105 (1), E167-E168 [citations: 0]
ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, … A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced … BMC genomics 2018: 19 (1), 37 [citations: 61]
K Pagacz, K Stawiski, A Szadkowska, W Mlynarski, W Fendler GlyCulator2: an update on a web application for calculation of glycemic variability indices Acta diabetologica 2018: 55 (8), 877-880 [citations: 37]
A Puła, K Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized … Leukemia & Lymphoma 2018: 59 (5), 1084-1094 [citations: 24]
K Stawiski, I Pietrzak, W Młynarski, W Fendler, A Szadkowska NIRCa: An artificial neural network-based insulin resistance calculator Pediatric Diabetes 2018: 19 (2), 231-235 [citations: 15]
KM Elias, W Fendler, K Stawiski, SJ Fiascone, AF Vitonis, RS Berkowitz, … Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer elife 2017: 6, e28932 [citations: 174]
J Trelinska, I Dachowska, D Baranska, K Stawiski, K Kotulska, W Fendler, … Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study) Pediatric blood & cancer 2017: 64 (6), e26347 [citations: 37]
K Stawiski, J Trelińska, D Baranska, I Dachowska, K Kotulska, S Jóźwiak, … What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods Magnetic Resonance Materials in Physics, Biology and Medicine 2017: 30 (4), 397-405 [citations: 9]
KM Elias, W Fendler, K Stawiski, SJ Fiascone, AF Vitonis, RS Berkowitz, … Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. Elife eLife Sciences Publications Limited 2017: 6, e28932 [citations: 6]
A Pula, K Stawiski, M Braun, E Iskierka-Jazdzewska, T Robak A systematic review and meta-analysis of B-cell receptor signaling inhibitors in relapsed and refractory chronic lymphocytic leukemia LEUKEMIA & LYMPHOMA 2017: 58, 152-153 [citations: 0]
A Puła, KG Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej … Acta Haematologica Polonica 2017: 48 (Supl. 1) [citations: 0]
M Zakrzewska, W Fendler, K Stawiski, R Gruszka, K Zakrzewski, … Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glial Tumors PEDIATRIC BLOOD & CANCER 2017: 64, S318-S318 [citations: 0]
LJ Lee, BE Howitt, W Fendler, K Stawiski, P Bu, L Cho, D Chowdhury, … miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC). Journal of Clinical Oncology 2017: 35 (15_suppl), e17116-e17116 [citations: 0]
KM Elias, WF Fendler, K Stawiski, A Vitonis, RS Berkowitz, DW Cramer, … Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer. REPRODUCTIVE SCIENCES 2017: 24, 87A-87A [citations: 0]
Ł Dziki, A Puła, K Stawiski, B Mudza, M Włodarczyk, A Dziki Patients’ awareness of the prevention and treatment of colorectal cancer Polish Journal of Surgery 2015: 87, 459-463 [citations: 16]
K Stawiski, A Strzałka, A Puła, K Bijakowski PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders MEDINFO 2015: 2015: eHealth-enabled Health, 325-328 [citations: 10]
A Strzałka, K Stawiski, A Kaczmarek, A Kuchareczko, M Polguj, M Topol Analiza zmienności morfologicznych i topograficznych w zakresie struktur nerwowych i mięśniowych jamy pachowej (axillary fossa) w kontekście ich ewentualnych implikacji klinicznych Wydawnictwo Uniwersytetu Medycznego w Gdańsku 2013 [citations: 0]
Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski Ciazy nska, M Gottwald, L [citations: 4]
K Elias, U Smyczynska, K Stawiski, Z Nowicka, J Webber, J Kaplan, … Identification of BRCA1/2 mutation female carriers using circulating microRNA pro les screening: 10, 1 [citations: 0]
K Stawiski, Ł Kuncman, M Jobczyk, M Bilski, C Franzese, M Orzechowska, … Pre-Treatment Sacral Bone Geometry Predicts Radiation-Induced Lymphopenia in Prostate Cancer Available at SSRN: 650635 [citations: 0]

See the details on PubMed: https://link.konsta.com.pl/pubmed

Book chapters

Konrad Stawiski, Łukasz Polak, Wojciech Fendler, Jarosław Drożdż. Evidence-based medicine w kardiologii. WIELKA INTERNA: Kardiologia część 1 - wydanie II. Medical Tribune Polska 2018.
Konrad Stawiski, Jacek Fijuth. Sztuczna inteligencja w onkologii. Innowacyjna Onkologia: potrzeby, możliwości, system. PZWL 2020. ISBN 978-83-200-6032-4

Teaching and invited lectures

2025: “Jak sztuczna inteligencja może wpłynąć na zwiększenie możliwości realizacji radioterapii - praktyka i perspektywa?”, XI Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland. Program
2025: “Radioterapia w miejscowo zaawansowanym raku odbytnicy - należy eskalować leczenie systemowe”, Konferencja 4R “Dokąd zmierza nowoczesna radioterapia - Eskalacja czy Deeskalacja?”, Poland. Program
2025: “Optymalizacja radio-chemioterapii po przezcewkowej resekcji (TMT) w raku pęcherza moczowego w świetle aktualnych badań”, “MISSION POSSIBLE” - Precyzja i personalizacja w onkologii, CMEducation, Warsaw, Poland. Program
2025: “Leczenie trójmodalne vs cystectomia z leczeniem okołooperacyjnym - dla kogo co jest optymalnym wyborem?” - radiotherapist perspective, Uro-Onko Expert Meeting, CMEducation, Łódź, Poland. Program
2024: “Total Neoadjuvant Treatment w raku odbytnicy - czy jest już standardem? Kiedy eskalować, kiedy deeskalować intensywność leczenia?”, VIII Konferencja 4R - Radioterapeuci Radioterapeutom, Warsaw, Poland. Program
2024: “Synergia leczenia celowanego i radioterapii w badaniach klinicznych”, Precyzja i personalizacja - “MISSION POSSIBLE” w onkologii, CMEducation, Warsaw, Poland. Program
2024: “Pisanie prac naukowych w dobie AI”, educational lecture/materials for Young PTRO. Slides
2023: “Odmienne twarze Greja - dawki biologicznie równoważne w zależności od sposobu frakcjonowania i lokalizacji anatomicznej”, conference “Radioterapia stereotaktyczna w dobie leczenia celowanego”, Warsaw, Poland. Archived program
2023: “Wyniki badania klinicznego - analiza oraz ocena wartości”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Medical University in Wrocław, Poland.
2022: “Czy sztuczna inteligencja zastąpi człowieka w planowaniu leczenia promieniami?”, X Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland.
2022: “Deep artificial neural networks in the integration of the expression profile of circulating and intracellular miRNA molecules in pancreatic cancer patients”, Łódź Oncology Days, Łódź, Poland.
2022: “Time series analysis”, postgraduate studies “Elements of empirical research methodology in medicine and application of statistics in biomedical research”, Medical University of Łódź, Poland.
2022: “Introduction to Data Mining methods and the STATISTICA Data Miner system”, postgraduate studies “Elements of empirical research methodology in medicine and application of statistics in biomedical research”, Medical University of Łódź, Poland.
2021-2022: “Data in clinical trials (CRF) and database management”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Medical University in Wrocław, Poland.
2021-2022: “New Technologies in Clinical Trials. Big Data”, postgraduate studies “Non-commercial Clinical Research - Design, Implementation and Management”, Medical University in Wrocław, Poland.
2021: “Zastosowanie zaawansowanych narzędzi statystycznych i sztucznej inteligencji w prognozowaniu rokowania i odpowiedzi na leczenie w raku gruczołu krokowego”, “Rak stercza - wielodyscyplinarne podejście do terapii po niepowodzeniu leczenia miejscowego i w chorobie z przerzutami”, 90C webinar. Program
2021: “Testy diagnostyczne, modele predykcyjne (regresja logistyczna)”, youngPTRO scientific-biostatistical workshops, Young Division of the Polish Society of Radiation Oncology. Recording
2019: “Kobiety w nauce”, Pałacowy Salon Naukowy, Akademia Młodych Uczonych PAN, Jabłonna, Poland, with Beata Małachowska. Event page
2019: “Nauczanie głębokie jako technika zwiększania skuteczności biomarkerów molekularnych”, IX Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland. Archived program
2018: “Data mining to discover ovarian cancer signature in the miRNA serum profile”, Elias Lab Meeting, Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Boston, MA, USA.
2018: “From anatomy to artificial intelligence in oncology”, local science-outreach conference, Poland.

Clinical trials - selected commercial studies

TALAPRO-2 (B9991040 / NCT04052204): Phase III randomized study of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer; role: subinvestigator / site clinical team, GU oncology and systemic-therapy interface.
NC-6004-009 (NCT03771820): Phase Ib/II study of NC-6004, a nanoparticulate cisplatin formulation, plus pembrolizumab in advanced solid tumors; role: subinvestigator.
KEYNOTE-867 (MK-3475-867 / NCT03924869): Phase III randomized study of pembrolizumab with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer; role: subinvestigator, chemoradiotherapy/immunotherapy setting.
KEYNOTE-689 (MK-3475-689 / NCT03765918): Phase III study of pembrolizumab as neoadjuvant and adjuvant treatment for resectable locally advanced head-and-neck squamous-cell carcinoma; role: subinvestigator.
CALLA (D910SC00001 / NCT04550260): Phase III randomized study of durvalumab with chemoradiotherapy in locally advanced cervical cancer; role: subinvestigator, definitive chemoradiotherapy setting.

Research software, digital health projects and reproducible tools

rect-ril (Zenodo DOI: 10.5281/zenodo.19595346) - R/Python analysis pipeline and interactive calculator for predicting severe radiation-induced lymphopenia in rectal cancer; role: creator/maintainer; output: calculator, reproducible analysis package, GitHub release, Zenodo DOI.
RTpipeline - DICOM RT-to-analysis pipeline for dose-volume, radiomics, and machine-learning workflows; role: creator/maintainer; output: GitHub repository and documentation.
Somatic Likelihood Tiering - multi-evidence framework for tumor-only whole-exome sequencing variant triage; role: creator/maintainer; output: GitHub release and Zenodo DOI: 10.5281/zenodo.19572621.
Prostate AS-counselling calculators - open-access active-surveillance counselling calculators estimating biopsy-to-prostatectomy ISUP-upgrade risk (Jobczyk et al. 2026); role: creator/maintainer of the public calculators.
OmicSelector - R/Docker framework for biomarker signature selection, feature selection, and deep-learning model development from high-throughput omics and multidimensional datasets; role: creator/maintainer; initially developed for miRNA-seq, RNA-seq, and qPCR.
Notatnik Medyczny - selected digital-health project applying AI-assisted workflows to structured clinical documentation, including pre-visit intake, OCR, dictation, and quality-control components.
Notatnik Medyczny (ADK Prototype) - public hackathon entry demonstrating selected AI-assisted medical-documentation functions.
Radioonkolog.pl - clinical profile and patient information resource for radiotherapy consultations.
seq-pipeline - workspace for data-science projects and NGS pipelines.
OmicApp - Shiny application framework integrating OmicSelector and omics modeling workflows.
neurexam - interactive neurological examination assistant and electronic health record.
PancreApp - computational approach to individualizing nutritional therapy in chronic gastrointestinal disorders.

Certified courses

2025: Clinical Scholars Research Training programme, Harvard Medical School / Polish Medical Research Agency, advanced clinical research training.
2022: Single-cell RNA-seq data analysis workshop, Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA
2022: Bulk RNA-seq data analysis workshop (part 1 and 2), Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA
2016: “Computational Genomics” (Summer School), Max-Delbrück-Centre for Molecular Medicine, Berlin, Germany
2016: “Fundamentals of Digital Image and Video Processing” (Coursera ID: ULTLWMZSCYEZ), Northwestern University , Evanston, IL, USA

Skills

Clinical radiation oncology: genitourinary and gastrointestinal cancers; bladder-preserving trimodality therapy, prostate and rectal radiotherapy, SBRT/SRS, brachytherapy, radiochemotherapy, radioimmunotherapy, clinical trials, ward/team leadership, and multidisciplinary oncology care.
Translational oncology: radiomics, DICOM RT processing, dose-volume analytics, miRNA-seq, RNA-seq, single-cell RNA-seq, whole-exome sequencing, molecular biomarkers, radiation toxicity, and radiotherapy response modeling.
AI and biostatistics: prediction modeling, survival analysis, machine learning, deep learning, data mining, model validation, clinical decision tools, and reproducible research workflows.
Research software and digital-health projects: R, R Markdown, Shiny, Python, Docker, GitHub/Zenodo releases, web calculators, clinical documentation workflows, OCR, dictation, quality-control components, and secure web deployment.

Organizational activity

2024 - present: Editorial Board Member, BMC Cancer (Springer Nature).
2023 - 2026: Elected member, ESTRO AI in RT Focus Group, an international working group on artificial intelligence in radiation oncology.
2021 - present: Member of ESTRO (European Society for Radiotherapy and Oncology);
2019 - present: Member of the Polish Oncological Society;
2019 - present: Member of the Polish Society of Radiation Oncology;
2017 - 2018: Member of the program council, Kuźnia Młodych Talentów, Academy of Young Scholars of the Polish Academy of Sciences.
2014 - 2016: Individual Course of Studies at the Department of Biostatistics and Translational Medicine; tutor: Dr Wojciech Fendler;
2013 - 2015: President of the Student Scientific Society of the Medical University of Lodz.
2012 - 2013: Member of the Board of the Student Scientific Society of the Medical University of Lodz.
2012 - 2013: Individual Course of Studies at the Department of Neurosurgery and Oncology of the Nervous System; tutor: Dr Krzysztof Tybor;
2012 - 2015: Member of the Student Scientific Society at the Department of Neurosurgery;
2011 - 2015: Member of the Student Research Group at the Faculty of Normal and Clinical Anatomy;
2011 - 2015: International Association of Medical Students (IFMSA): (1) 2014: European Regional Meeting of Medicine Students, General Delegate of Poland, (2) 2013 - 2016: IFMSA New Technologies Support Division Director Assistant (international position), (3) 2013 - 2015: Member of the IFMSA-Poland marketing team (national position), (4) 2013 - 2015: IFMSA-Poland National New Technologies Director (national position), (5) 2012 - 2013: IFMSA-Poland National New Technologies Director Assistant (national position), (6) 2012 - 2013: Local coordinator of the project “Dying - a human thing” (local position), (7) 2011 - 2014: Local New Technologies Director (local position), (8) participation in 3 national IFMSA-Poland assemblies (Fall 2012, Spring 2012, Fall 2013).

This English CV was updated on 2026-07-09.

Jestem lekarzem specjalistą radioterapii onkologicznej i badaczem zajmującym się radioterapią kliniczną, data science w onkologii, biomarkerami molekularnymi, radiomiką i praktycznymi zastosowaniami AI w medycynie. Klinicznie zajmuję się szerokim zakresem radioterapii, ze szczególnym uwzględnieniem nowotworów układu moczowo-płciowego i przewodu pokarmowego.

Imię i nazwisko: Konrad Grzegorz Stawiski
Obywatelstwo: polskie
E-maile: konrad@konsta.com.pl, konrad.stawiski@umed.lodz.pl, konradg_stawiski@dfci.harvard.edu, kstawisk@broadinstitute.org
Wybrane linki: Harvard Catalyst, Radioonkolog.pl, ORCID, PubMed, OpenAlex, Google Scholar, GitHub

Profil akademicki Pełne CV

Podsumowanie

Konrad G. Stawiski jest lekarzem specjalistą radioterapii onkologicznej i badaczem kliniczno-translacyjnym zajmującym się radioterapią nowotworów układu moczowo-płciowego i przewodu pokarmowego, leczeniem raka pęcherza, prostaty i odbytnicy, radiomiką, biomarkerami omicznymi, modelowaniem toksyczności radioterapii oraz praktycznymi zastosowaniami AI w medycynie.

Pełni funkcję Visiting Assistant Professor of Radiation Oncology w Dana-Farber Cancer Institute, jest adiunktem Uniwersytetu Medycznego w Łodzi oraz zastępcą kierownika 34-łóżkowego Oddziału Brachyterapii i Onkologii Ogólnej w Szpitalu im. M. Kopernika w Łodzi.

Aktualny profil Google Scholar obejmuje 97 rekordów, H-index 19 oraz 1 095 cytowań. Jest Partner PI i liderem polskiej grupy w konsorcjum ERA PerMed miRPOC, kierownikiem projektów NCN PRELUDIUM i Radonek-AI, współtwórcą rodzin patentowych dotyczących krążących mikroRNA oraz członkiem zespołów badawczych w badaniach klinicznych faz I/II-III.

Jego dorobek obejmuje wybrane otwarte oprogramowanie badawcze i projekty digital health, badania biomarkerów translacyjnych, potoki analizy danych radioterapeutycznych, prace z zakresu AI klinicznego oraz działalność redakcyjną jako Editorial Board Member w BMC Cancer.

Doświadczenie zawodowe

2026 - obecnie: Visiting Assistant Professor of Radiation Oncology, Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
2024 - obecnie: Adiunkt, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
- Opiekun Studenckiego Koła Naukowego “Sztuczna Inteligencja w Onkologii”.
- Prowadzenie zajęć dydaktycznych z zakresu biostatystyki, medycyny translacyjnej, metodologii badań, data mining, deep learning i zastosowań AI.
- Badania onkologiczne obejmujące bioinformatykę i analizę danych omicznych: radiomika, NGS, miRNA-seq, bulk/sc RNA-seq i WXS.
- Lider polskiej grupy w międzynarodowym konsorcjum ERA PerMed miRPOC.
2023 - obecnie: Lekarz specjalista radioterapii onkologicznej, Zastępca Kierownika Oddziału Brachyterapii i Onkologii Ogólnej, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Łódź.
- Zastępca lekarza kierującego 34-łóżkowym oddziałem, koordynujący radioterapię zewnętrzną, brachyterapię, jednoczasową radiochemioterapię i opiekę kliniczną w oddziale onkologii ogólnej.
- Szeroka praktyka w radioterapii onkologicznej ze szczególnym naciskiem na nowotwory układu moczowo-płciowego i przewodu pokarmowego, zwłaszcza raka prostaty, raka pęcherza moczowego i raka odbytnicy.
- Doświadczenie w radioterapii prostaty, leczeniu trójmodalnym raka pęcherza, radiochemioterapii raka odbytnicy, SBRT, SRS, radiochemioterapii i radioimmunoterapii.
- Subinvestigator w komercyjnych i niekomercyjnych badaniach klinicznych.
2022 - 2023: Research Fellow in Radiation Oncology, Dana-Farber Cancer Institute / Harvard Medical School / Broad Institute of MIT and Harvard, Boston, MA, USA.
2021 - 2023: Asystent naukowo-dydaktyczny, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
2018 - 2023: Lekarz rezydent radioterapii onkologicznej, Regionalny Ośrodek Onkologiczny, Szpital im. M. Kopernika w Łodzi.
- Praca lekarska w Zakładzie Radioterapii oraz dyżury w Oddziale Radioterapii i Onkologii (referencja: prof. Jacek Fijuth, M.D., Ph.D.).
- Dodatkowe doświadczenie dyżurowe w Oddziale Hematoonkologii (referencja: prof. Piotr Smolewski, M.D., Ph.D.).
2017 - 2018: Specjalista bioinformatyki i informatyki medycznej, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
2016 - 2017: Staż podyplomowy, Szpital MSWiA w Łodzi.

Profil kliniczny, badawczy i programistyczny

Szeroka praktyka radioterapeutyczna ze szczególnym uwzględnieniem nowotworów układu moczowo-płciowego i przewodu pokarmowego; radiomika i przetwarzanie danych radioterapeutycznych; biomarkery translacyjne; powtarzalne analizy onkologiczne; oraz wybrane projekty oprogramowania badawczego i digital health.

Profil akademickiZwięzłe naukowe CV do recenzji, współpracy i kontaktów instytucjonalnych.

Polski PDF Polski DOCX Angielski PDF Angielski DOCX

Pełne CV akademickieKompletny życiorys z pełnym rekordem publikacji i szczegółową działalnością organizacyjną.

Pełny PDF po polsku Pełny DOCX po polsku Pełny PDF po angielsku Pełny DOCX po angielsku

Kontakt

Działalność kliniczno-translacyjna

Od praktyki klinicznej do narzędzi i publikacji

Radioterapia klinicznanowotwory układu moczowo-płciowego i przewodu pokarmowego, SBRT/SRS, brachyterapia, radiochemioterapia

Dane i dowodyDICOM RT, radiomika, miRNA, RNA-seq, WXS, dane kliniczne

Analiza i walidacjaBiostatystyka, machine learning, zinterpretowalne kalkulatory ryzyka

RezultatyBadania kliniczne, publikacje, open source, projekty digital health, materiały dla pacjentów

Obszary specjalizacji

Radioterapia onkologiczna Biomarkery i obrazowanie AI w medycynie Open source

Wykształcenie

2023: Specjalizacja z radioterapii onkologicznej, Centrum Egzaminów Medycznych.
2016 - 2021: Doktor nauk medycznych, Zakład Biostatystyki i Medycyny Translacyjnej, Uniwersytet Medyczny w Łodzi.
- Rozprawa: Głębokie sztuczne sieci neuronowe w integracji profilu ekspresji krążących i wewnątrzkomórkowych cząsteczek miRNA pacjentów z rakiem trzustki.
2017: Prawo wykonywania zawodu lekarza w Polsce (PWZ: 3347648).
2010 - 2016: Lekarz, 6-letni kierunek lekarski, Wydział Lekarski, Uniwersytet Medyczny w Łodzi; wynik końcowy: bardzo dobry.

Staże i pobyty naukowe

2026: Stypendium im. prof. Franciszka Walczaka NAWA na 6-miesięczny pobyt badawczy w Dana-Farber Cancer Institute / Harvard Medical School, dotyczący badań nad radioterapią raka pęcherza, w tym strategiami oszczędzającymi pęcherz.
2022 - 2023: Stypendium NAWA Bekker, 6-miesięczny pobyt badawczy w Dana-Farber Cancer Institute / Harvard Medical School / Broad Institute of MIT and Harvard, Boston, MA, USA (referencja: Kent Mouw, M.D., Ph.D.).
2016: Staż badawczy ERASMUS+ w EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging, University of Cambridge, Cambridge, UK; projekt dotyczący oprogramowania do fuzji TRUS-MRI w czasie rzeczywistym w biopsji raka prostaty (referencja: prof. John Aston, Ph.D.).
2015: IFMSA research exchange (6 tygodni), Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Upstate Medical University, Syracuse, NY, USA (referencja: Stephen J. Glatt, Ph.D.).
2014: Staż kliniczny neurochirurgiczny (3 tygodnie), University Hospital Southampton NHS Trust, Southampton, UK (referencja: Paul Grundy, M.D.).
2013: Staż kliniczny (4 tygodnie), Mubarak Al Kabeer Hospital, Kuwait City, Kuwait (referencja: Ibrahim T. Lasheen, M.D.).

Granty, projekty finansowane i innowacje

2023 - obecnie: ERA PerMed Consortium, Joint Transnational Call 2022, miRPOC, miRNA jako biomarkery wczesnego wykrywania i personalizacji leczenia raka jajnika; całkowity budżet konsorcjum ok. 1 000 000 EUR; Partner PI / lider polskiej grupy w Uniwersytecie Medycznym w Łodzi; konsorcjum z Cancer Registry of Norway / Oslo University Hospital, German Cancer Research Center oraz Brigham and Women’s Hospital / Harvard Medical School.
2023 - 2024: Radonek-AI - wirtualny asystent pacjenta u onkologa-radioterapeuty, 70 000 PLN, program “Studenckie koła naukowe tworzą innowacje”, Ministerstwo Edukacji; PI.
2019 - 2022: NCN PRELUDIUM [UMO-2018/29/N/NZ5/02422], głębokie sieci neuronowe w integracji profilu ekspresji krążących i wewnątrzkomórkowych cząsteczek miRNA u pacjentów z rakiem trzustki, 209 860 PLN; PI.
2014 - 2015: Ministerstwo Nauki i Szkolnictwa Wyższego, “Generacja Przyszłości” [MNiSw/2014/DIR/379/GPII], PancreApp: zastosowanie ośmiowymiarowej aproksymacji Sheparda w indywidualizacji zaleceń żywieniowych, zwłaszcza w przewlekłych chorobach trzustki, 37 800 PLN; PI.
2017 - 2018: specjalista bioinformatyki i informatyki medycznej w projekcie “Łódzki Program Profilaktyki Nowotworów Głowy i Szyi” [POWR.05.01.00-00-0011/16], współfinansowanym ze środków Unii Europejskiej w ramach Europejskiego Funduszu Społecznego, 1 792 260 PLN; budowa platformy internetowej do zbierania danych badawczych.
2019 - 2021: badacz w projekcie “Predictive Biomarkers of Radiation Toxicity (PBRTox)” [POIR.04.04.00-00-2280/16] pod kierunkiem prof. Wojciecha Fendlera, Fundacja na rzecz Nauki Polskiej, 1 999 651 PLN.
2014 - 2016: badacz w projekcie “Profil krążących mikroRNA w diagnostyce rzadkich postaci cukrzycy” [2012/05/E/NZ5/02130] pod kierunkiem prof. Wojciecha Fendlera, NCN SONATA BIS, 1 489 800 PLN.

Nagrody, wyróżnienia i stypendia

2025: Stypendium Programu im. prof. Franciszka Walczaka NAWA, Narodowa Agencja Wymiany Akademickiej; jeden z 31 laureatów wybranych spośród 125 wniosków w naborze 2025 (25% współczynnik sukcesu; finansowanie do 29 500 PLN miesięcznie), na 6-miesięczny pobyt w Dana-Farber Cancer Institute / Harvard Medical School dotyczący strategii leczenia oszczędzającego pęcherz w raku pęcherza naciekającym mięśniówkę; raport uczelni: ocena wniosku 94/100.
2025: Pierwsze miejsce za projekt końcowy w programie Clinical Scholars Research Training, Harvard Medical School / Agencja Badań Medycznych.
2022: Nagroda Rektora Uniwersytetu Medycznego w Łodzi za osiągnięcia naukowe w 2021 r., nagroda zespołowa za cykl publikacji dotyczących nowotworów urologicznych.
2022: Najlepsza rozprawa doktorska z biostatystyki w 2021 r. według StatSoft Polska.
2022: Nagroda Ministra Nauki za działalność wdrożeniową związaną z testami diagnostycznymi opartymi na krążących mikroRNA.
2021: Stypendium Fundacji Naukowej Polpharmy dla najlepszych doktorantów.
2020: Stypendium dla najlepszych doktorantów Uniwersytetu Medycznego w Łodzi.
2019: Stypendium dla najlepszych doktorantów Uniwersytetu Medycznego w Łodzi.
2018: Stypendium dla najlepszych doktorantów Uniwersytetu Medycznego w Łodzi.
2017: Stypendium dla najlepszych doktorantów Uniwersytetu Medycznego w Łodzi.
2016: Stypendium dla najlepszych doktorantów Uniwersytetu Medycznego w Łodzi.
2016: Stypendium Miasta Łodzi dla najlepszych doktorantów.
2016: Zwycięzca konkursu Adzuna “Graduate of the Year”.
2015: Stypendium Ministra Nauki i Szkolnictwa Wyższego oraz Ministra Zdrowia za wybitne osiągnięcia.
2015: Stypendium Marszałka Województwa Łódzkiego najwyższego stopnia.
2014: Wyróżnienie w konkursie “Studencki Nobel”.
2014: Nagroda specjalna dla najmłodszego laureata sesji podczas 10. International & 52. Polish Training & Scientific Medical Congress of Students’ Scientific Societies and Junior Doctors “Juvenes Pro Medicina” 2014 w Łodzi (fundator: Aldona Ochęcka-Szymańska, M.D., Ph.D.).
2013: Stypendium Ministra Nauki i Szkolnictwa Wyższego za wybitne osiągnięcia.

Patenty i komercjalizacje

WO2023283476A2, CA3223723A1, AU2022306397A1: “Circulating microRNA signatures for pancreatic cancer”.
EP3565903, US20200123614A1, US11214839B2, US12385099: “Circulating microRNA signatures for ovarian cancer”; rodzina patentowa publicznie opisywana jako objęta próbami komercjalizacji/licencjonowania z Aspira Women’s Health (A15876-ELA-ASPIRA).

Badania i publikacje

H-index według Google Scholar: 19
(cytowania = 1095; prace/abstrakty = 97)

Pełne rekordy publikacji: PubMed, ORCID, OpenAlex, Google Scholar.

Wybrane publikacje i wkład

Pierwszy autor / translacyjna onkologia układu moczowego: Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma. Molecular Oncology. 2026 Jun 1. doi: 10.1002/1878-0261.70276. Wkład: pierwszy autor; mikrośrodowisko immunologiczne guza w zaawansowanym raku urotelialnym leczonym platyną.
Rak pęcherza / współpraca DFCI-Broad: Zhou Y, Borcsok J, Adib E, Kamran SC, Neil AJ, Stawiski K, et al. ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer. Science Advances. 2023;9:eadg2263. doi: 10.1126/sciadv.adg2263. Wkład: współautor w translacyjnym projekcie dotyczącym raka pęcherza, zgodnym z kierunkiem badań nad leczeniem oszczędzającym pęcherz.
AI kliniczne / uroonkologia: Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Różański W, Soria F, et al. Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer. European Urology Oncology. 2022;5:109-112. Wkład: współpraca w zakresie AI klinicznego i modeli predykcyjnych.
Oprogramowanie badawcze / modelowanie danych omicznych: Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczyński A, et al. OmicSelector: automatic feature selection and deep learning modeling for omic experiments. bioRxiv. 2022. doi: 10.1101/2022.06.01.494299. Wkład: pierwszy autor i główny twórca oprogramowania.
Walidacja biomarkerów miRNA: Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, et al. Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches. Frontiers in Oncology. 2024;14:1389066. Wkład: pierwszy autor; walidacja krążących biomarkerów miRNA z użyciem uczenia maszynowego.
Diagnostyka translacyjna powiązana z patentami: Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, et al. Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. eLife. 2017;6:e28932. Wkład: współpraca obliczeniowa w pracy translacyjnej powiązanej z rodziną patentową.
Biomarkery odpowiedzi na promieniowanie: Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, et al. Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study. Radiotherapy and Oncology. 2023;185:109731. Wkład: współpraca w zakresie biomarkerów i odpowiedzi na promieniowanie.
Toksyczność radioterapii / analizy dose-volume: Nowicka Z, Kuna K, Łaszczych M, Łazar-Poniatowska M, Sobocki BK, Stawiski K, et al. Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques. Physics and Imaging in Radiation Oncology. 2024;30:100593. Wkład: współpraca w zakresie danych radioterapeutycznych i modelowania predykcyjnego.

97rekordów Google Scholar

1 095cytowań Google Scholar